ReposiTrak saw an improvement in its IBD SmartSelect Composite Rating Wednesday, from 94 to 96.
The new score means the company is now outperforming 96% of all stocks in terms of the most important fundamental and technical stock-picking criteria. History shows the top market performers tend to have a 95 or higher score as they launch their major climbs.
ReposiTrak is not currently near a proper buy point. Look for the stock to form and break out of a new base. Keep in mind that it's a very thinly traded stock, with average daily dollar volume of just $987,389..
Lean How — And When — To Sell Stocks
The stock sports a 93 EPS Rating, meaning its recent quarterly and annual earnings growth is outpacing 93% of all stocks.
Its Accumulation/Distribution Rating of B- shows moderate buying by institutional investors over the last 13 weeks.
The company reported a 14% EPS gain for Q2. Sales growth came in at 7%, down from 8% in the prior quarter.
ReposiTrak holds the No. 6 rank among its peers in the Computer Software-Special Enterprise industry group. Descartes Systems Group, Atlassian Cl A and HubSpot are among the top 5 highly-rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
